加载中
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
前收盘价
US$0.5931
−US$0.0113 · -1.87%
盘后
US$0.59
−US$0.0031 · -0.52%
10月12日 18:23 ET
盘中时间采用ET。市场数据可能有所延迟。
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
日内区间
当前US$0.5931
52周区间
当前US$0.5931
盘中时间采用ET。市场数据可能有所延迟。
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
日内区间
当前US$0.5931
52周区间
当前US$0.5931
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 150.26万 USD | 58.32万 USD | — | — |
| 销货成本 | — | 936.35万 USD | 7052 USD | 1640.23万 USD | 27.17万 USD |
| 毛利 | — | −786.1万 USD | 57.62万 USD | −1640.23万 USD | −27.17万 USD |
| 研究与开发 | 704.3万 USD | 936.35万 USD | 762.75万 USD | 9242.25万 USD | 2389.59万 USD |
| 销售、一般及管理费用 | 647.66万 USD | 645.87万 USD | 842.07万 USD | 2096.98万 USD | 1355.05万 USD |
| 营业费用 | 1323.38万 USD | 645.87万 USD | 1604.81万 USD | 9699万 USD | 3717.47万 USD |
| 利息收入 | 65.21万 USD | 128.91万 USD | 122.41万 USD | 44.87万 USD | 1648 USD |
| 利息支出 | — | — | — | 44.87万 USD | — |
| 折旧和摊销 | 2.17万 USD | 2.23万 USD | 7052 USD | 18.64万 USD | 27.17万 USD |
| 营业利润 | −1323.38万 USD | −1431.97万 USD | −1547.2万 USD | −1.13亿 USD | −3744.64万 USD |
| 净利润 | −1259.96万 USD | −1295.87万 USD | −1428.68万 USD | −1.13亿 USD | −3653.66万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年2月13日 | 1:20 | — | — |
已生效 2023年2月13日
1:20
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
